Hims & Hers Weight LossvsHenry Meds GLP-1

Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone released after eating. It slows stomach emptying, signals fullness to the brain's appetite centers, and reduces hunger and food "noise," so people tend to eat less. It also stimulates insulin secretion and helps with blood-sugar control. "Compounded" semaglutide is the same molecule custom-mixed by a pharmacy rather than mass-manufactured and FDA-approved like Wegovy or Ozempic. Hims sold it (typically as a self-injected liquid drawn from a multi-dose vial, and later an oral form) under the temporary legal allowance that existed only while branded semaglutide was officially in shortage.

Henry Meds prescribes compounded versions of GLP-1 receptor agonists, primarily semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound). These drugs mimic the gut hormone GLP-1 (tirzepatide also mimics GIP), which slows stomach emptying, signals fullness to the brain, and improves how the body regulates blood sugar and appetite. The result is reduced hunger, smaller portions, and weight loss. "Compounded" means a licensed pharmacy mixes the medication rather than it being a mass-produced, FDA-approved finished product; the FDA has warned that some compounders have used unapproved salt forms (such as semaglutide sodium or acetate) that differ from the base molecule in the approved drugs.

The efficacy data comes from branded semaglutide, since compounded copies are not separately tested in clinical trials. In the pivotal STEP 1 trial (Wilding et al., NEJM 2021; 1,961 adults), once-weekly injectable semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo, and 86.4% of treated participants lost at least 5% of body weight. The newer oral semaglutide 25 mg (OASIS 4 trial, 64 weeks) showed a mean loss of about 13.6% when counting all randomized participants regardless of whether they stopped treatment, and roughly 16.6% among those who stayed on the drug, versus about 2.4-2.7% with placebo. Compounded products that genuinely contain correctly dosed, properly sourced semaglutide would be expected to perform comparably because it is the same molecule — but their purity, potency, and consistency are not FDA-verified, so individual results and safety can vary.

Henry Meds has not published its own clinical trials; efficacy is inferred from studies of the same active molecules. In the pivotal STEP 1 trial (NEJM 2021, 1,961 adults over 68 weeks), once-weekly 2.4 mg semaglutide produced a mean 14.9% reduction in body weight versus 2.4% with placebo, and 86.4% of participants lost at least 5% of their body weight. Tirzepatide produced even larger average losses in its SURMOUNT program. Important caveat: compounded products are not FDA-approved and are not tested for the same bioequivalence, and Henry Meds' lower-strength and oral/sublingual formulations lack the trial evidence that supports the brand injectables, so individual results may differ and could be lower than the trial figures.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate, worst when the dose increases, and often easing over time. Less common but serious risks include pancreatitis, gallstones, kidney injury from dehydration, low blood sugar (especially when combined with diabetes medicines), and a boxed warning for thyroid C-cell tumors based on rodent studies. A distinct risk specific to compounded multi-dose vials: the FDA has logged adverse-event reports — more than 500 for compounded semaglutide as of 2025 — tied largely to self-dosing errors, including cases where patients drew 5 to 20 times the intended dose by confusing milligrams, milliliters, and "units," with some events requiring hospitalization. Always confirm the exact dose and units with your prescriber before injecting, and seek medical care if you suspect an overdose.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are usually mild-to-moderate and worst during dose escalation. In STEP 1, about 4.5% of semaglutide users discontinued because of GI effects versus 0.8% on placebo. Serious but rarer risks include acute pancreatitis (severe abdominal pain), gallbladder disease, kidney injury from dehydration, and low blood sugar (especially when combined with other diabetes medications). All GLP-1 drugs in this class carry a boxed warning for thyroid C-cell tumors seen in rodents. The FDA has separately flagged compounded products for dosing errors and quality issues, including multiple adverse-event reports, some requiring hospitalization, tied to incorrect self-measured doses.

As of 2026, the compounded semaglutide that made Hims popular ran roughly $150-$250 per month, with promotional first-month or longer-plan offers sometimes advertised lower. With the program winding down, new Hims patients are generally directed to FDA-approved options: branded injectable Wegovy and the oral Wegovy pill have been advertised on the platform in roughly the $249-$299/month range and Zepbound somewhat higher (around $399/month), with some lower-cost subscription plans advertised from about $149/month. Crucially, these are cash/subscription prices; with commercial insurance plus a manufacturer savings card, branded Wegovy can drop to as little as $0-$25/month for eligible patients — often making an approved drug cheaper than people expect. Prices change frequently and vary by plan and eligibility; confirm current figures directly with Hims and check your insurance coverage.

As of September 2026, Henry Meds says its GLP-1 treatment starts at $179/month and that the price includes provider visits, medication, supplies and ongoing support, with the exact amount varying by treatment plan and dose. There is no separate membership fee. Compounded GLP-1s are essentially never covered by insurance, so plan to pay out of pocket. Note BBB complaints about auto-renewal billing, unexpected price increases and refunds: cancel before renewal and confirm the current price at signup.

Branded semaglutide (Wegovy) is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, used alongside a reduced-calorie diet and increased physical activity. Hims's telehealth model requires an online medical consultation. You should NOT use semaglutide if you or a family member has a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you've had a serious allergic reaction to it. It is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and should be used cautiously with a history of pancreatitis, gallbladder disease, kidney problems, or severe gastrointestinal disease. Per FDA guidance, compounded versions specifically should be reserved for patients whose needs genuinely cannot be met by an FDA-approved product. Only a qualified clinician can determine whether semaglutide is appropriate for you.

Generally aimed at adults seeking weight management who meet clinical criteria assessed during the telehealth intake, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol. You must NOT use these drugs if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are contraindicated in pregnancy and breastfeeding, generally avoided with a history of pancreatitis, and require caution with gallbladder disease, diabetic retinopathy, or severe gastrointestinal disease. Your prescriber makes the final eligibility call. Anyone whose insurance covers FDA-approved Wegovy or Zepbound should weigh those first.